Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Video
Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency
Author(s):
Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.
Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:
- For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
- Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
- Chronic immune thrombocytopenia (ITP) in adults.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Videos
Related Content
